Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Shanghai InnoStar Bio-tech Co's EV-to-FCF or its related term are showing as below:
SHSE:688710'
s EV-to-FCF Range Over the Past 10 Years
Min: -191.89 Med: -11.71 Max: 106.11
Current: 94.18
During the past 7 years, the highest EV-to-FCF of Shanghai InnoStar Bio-tech Co was 106.11. The lowest was -191.89. And the median was -11.71.
SHSE:688710's EV-to-FCF is ranked worse than 85.31% of 565
companies
in the Drug Manufacturers industry
Industry Median: 20.96
vs SHSE:688710: 94.18
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shanghai InnoStar Bio-tech Co (SHSE:688710) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shanghai InnoStar Bio-tech Co's PE Ratio (TTM) for today is calculated as:
Shanghai InnoStar Bio-tech Co's share price for today is ¥71.27.
Shanghai InnoStar Bio-tech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-0.170.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Shanghai InnoStar Bio-tech Co EV-to-FCF Related Terms
Shanghai InnoStar Bio-tech Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688710 vs LLY, JNJ, ABBV: EV-to-FCF Comparison
For the Drug Manufacturers - General subindustry, Shanghai InnoStar Bio-tech Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai InnoStar Bio-tech Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shanghai InnoStar Bio-tech Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Shanghai InnoStar Bio-tech Co's EV-to-FCF falls into.
Shanghai InnoStar Bio-tech Co's current Enterprise Value is ¥8,335.2 Mil.
Shanghai InnoStar Bio-tech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥88.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai InnoStar Bio-tech Co (SHSE:688710) has a EV-to-FCF of 94.18 as of Jul. 20, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shanghai InnoStar Bio-tech Co and its competitors. According to the industry distribution chart, Shanghai InnoStar Bio-tech Co ranks #482 out of 565 companies in the Drug Manufacturers industry, placing it in the top 85.3%.
Is Shanghai InnoStar Bio-tech Co's EV-to-FCF too high?
Shanghai InnoStar Bio-tech Co's current EV-to-FCF is 94.18. The Drug Manufacturers industry median EV-to-FCF is 20.96. Shanghai InnoStar Bio-tech Co's value of 94.18 is 349.3% above this industry median. Based on the distribution chart, Shanghai InnoStar Bio-tech Co ranks #482 out of 565 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shanghai InnoStar Bio-tech Co has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai InnoStar Bio-tech Co's EV-to-FCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Shanghai InnoStar Bio-tech Co ranks #482 out of 565 companies for EV-to-FCF. This places Shanghai InnoStar Bio-tech Co in the lower half of its industry. The industry median EV-to-FCF is 20.96. Shanghai InnoStar Bio-tech Co's value of 94.18 is 349.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.96, based on 565 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai InnoStar Bio-tech Co's current EV-to-FCF of 94.18 is 349.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shanghai InnoStar Bio-tech Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai InnoStar Bio-tech Co's current EV-to-FCF is 94.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai InnoStar Bio-tech Co stock overvalued right now?
Shanghai InnoStar Bio-tech Co (SHSE:688710) has a current EV-to-FCF of 94.18. The current EV-to-FCF is 94.18 and 349.3% above the Drug Manufacturers industry median of 20.96. Shanghai InnoStar Bio-tech Co's overall GF Score™ is 35/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Shanghai InnoStar Bio-tech Co (SHSE:688710), the current EV-to-FCF is 94.18 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shanghai InnoStar Bio-tech Co Business Description
Shanghai InnoStar Bio-tech Co Ltd is a comprehensive research and development services (CRO) enterprise that specializes in providing biomedical non-clinical research services.
35GF Score
Get the complete analysis for SHSE:688710
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688710 has been successfully added to your 
